Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful hard but unsuccessfully to create a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. My first CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire interview that I came away with an inadequate viewpoint of the company.

Irony of irony, the bad impression of mine of the business enterprise has grown steadily, although the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise as well as associated intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) as well as the first new drug program approval ($5 million), as well as royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and numerous indications, it’s this single remedy as well as a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, several disease types, multiple delivering presentations and multiple publications.

Can it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really beginning of the interest of mine in this particular business. Judging by the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *